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To the Editor,
Psychiatric comorbidity is extremely common in bipolar dis-
order (BD). More than half of BD patients have an additional 
diagnosis, one of the most difficult to manage being obsessive-
compulsive disorder (OCD).
The majority of BD-OCD patients experienced the onset 
of OCD prior to the onset of BD and presented higher preva-
lence of family history for mood disorders versus non-BD-
OCD patients.1,2 Moreover, comorbid BD and OCD cycled to-
gether, with OC symptoms often remitting during manic/
hypomanic episodes.3
Treating BD-OCD patients remains a great challenge. Though 
serotonin reuptake inhibitors (SRIs) are the first line treatment 
for OCD, they can induce mood instability in BD, especially if 
administered at high doses and maintained for a long time.
We present the case of a severe BD-OCD patient who ex-
perienced complete remission with aripiprazole augmentation 
to mood stabilizer.
The patient is a 22-year-old Caucasian unmarried woman 
with positive family history for major depressive disorder. From 
the age of 16, she had presented fear of contamination, wash-
ing and cleaning rituals that had partially impaired her func-
tional capacity. These symptoms met Diagnostic and Statisti-
cal Manual of Mental Disorders-fifth Edition (DSM-5) criteria 
for OCD and were untreated for four years. No history of man-
ic or depressive episodes was reported.
At the age of 20 the obsessions and compulsions increased 
and she presented with depressed mood and feelings of worth-
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lessness. She was admitted to the inpatient service and treat-
ed with fluoxetine 40 mg/day; obsessive-compulsive and af-
fective symptoms were well controlled and satisfactory quality 
of life was regained.
After three months on fluoxetine 40 mg/day, she developed 
a manic episode. Her therapy was modified to lithium carbon-
ate 900 mg/day (serum level achieved, 0.8–0.9 mEq/L) and 
olanzapine 20 mg/day. Olanzapine was gradually decreased 
and lithium carbonate was continued with only partial remis-
sion of obsessive-compulsive symptoms and mood stabilization.
After six months, intrusive and persistent thoughts and com-
pulsive rituals increased prominently. Aripiprazole 10 mg/day 
was added to lithium carbonate and complete remission of bi-
polar and obsessive-compulsive symptoms for the following 
twelve months was reported.
Aripiprazole is the first approved atypical antipsychotic with 
a mechanism of action that exerts a partial agonism with high 
affinity at Dopamin D2 and Serotonin-5-HT1A receptors as well 
as an antagonism at Serotonin-5-HT2A receptors. Its peculiar 
pharmacodynamic profile might support a favorable influence 
on negative symptoms and cognitive dysfunctions in schizo-
phrenic patients, managing acute mania and stabilization phas-
es in BD, and in addition to SRIs in refractory OCD.4 This case 
report describes the efficacy of aripiprazole augmentation to 
lithium carbonate also as maintenance therapy in BD-OCD.
The DSM explicitly produces overlapping clinical criteria for 
many diagnoses, especially mood and anxiety disorders, guar-
anteeing comorbidity in quite a different sense than in the medi-
cal meaning of the term as co-occurrence of independent dis-
eases. Using DSM definition, it is unclear whether concomitant 
diagnoses actually reflect the presence of distinct clinical en-
tities or refer to multiple manifestations of a single clinical entity.
On the contrary, in the hierarchical approach, advocated in 
classic European psychopathology, anxiety presentations, like 
OCD, are not diagnosed as separate conditions when co-oc-
curring with mood presentations, like BD. In other words, OCD 
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was not diagnosed unless BD was ruled out. If correct, as seems 
to be the case based on the available literature, OCD patients 
should be evaluated about family history for mood disorders 
and other evidence of bipolarity. 
If most OCD symptoms are secondary to BD, then it may 
be that both groups of symptoms may respond to adequate 
mood stabilizer treatment.5 Due to the risk of switching to 
mania in patients treated with SRIs, aripiprazole augmenta-
tion to mood stabilizers can be consider as an alternative treat-
ment strategy in treatment-resistance comorbid patients. Ad-
dition of SRIs may be needed only in a minority of BD patients 
with refractory OCD. Benefit with other antipsychotics was 
also seen, although a few reports also exist of exacerbation of 
OC symptoms with neuroleptic agents.
To allow more definitive conclusions, prospective controlled 
studies are needed in this important diagnostic and clinical 
topic. 
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